This amplification is targetable with high sensitivity to FGFR inhibitors in vitro (52), an FGFR2-targeting antibody showed potent antitumor activity against human cancers in pre-clinical studies (54) and several FGFR tyrosine-kinase inhibitors are in clinical trials (54–56). The gene discussed is FGFR2; the disease is cancer.